 This is a single-centre, open-label, dose finding study using induced blood stage malaria IBSM infection to characterize the pharmacodynamic interaction between OZ439 and DSM265, administered around 120 minutes apart for treatment of early Plasmodium falciparum blood stage infection. The study will be conducted in up to three cohorts n8 per cohort using different doses of OZ439 and DSM265. The doses of OZ439 and DSM265 that will be investigated in the first cohort will be 200 mg of OZ439 and 100mg of DSM265, both administered as single doses around 120 minutes apart. Subsequent doses in subsequent cohorts will be determined following a review of observed OZ439 and DSM265 safety, and pharmacokinetic and pharmacodynamic interaction outcomes, particularly the antimalarial activity of the drugs given in combination as defined by parasite clearance kinetics. The doses used in Cohort 2 and 3 may be adjusted but will not exceed the maximum acceptable doses predefined for this study which are 400 mg for DSM265 and 500mg for OZ439 as determined in previous safety and pilot efficacy studies. The dose will be determined by the funding sponsor and the principal investigator PI following Safety Review team SRT and scientific evaluation. If no safe alternative dose can be determined the option exists to curtail the study to less than three cohorts. 